BrightSpring posted Q4 2025 net revenue of USD 3.6 billion, up 29.3%, with gross profit of USD 413 million, up 21.8%. Q4 net income from continuing operations was USD 49.6 million and Adjusted EBITDA was USD 184 million, up 40.7%. For FY 2025, net revenue was USD 12.9 billion, up 28.2%, with gross profit of USD 1.5 billion, up 19.8%. FY net income from continuing operations was USD 104.8 million and operating cash flow was USD 490 million; Adjusted EBITDA was USD 618 million, up 34.2%. Leverage was 2.99x at December 31, 2025. During the quarter, BrightSpring acquired 107 home health and hospice branches as part of the Amedisys and LHC acquisition and repurchased 1.5 million shares for about USD 43.2 million in connection with an October 2025 secondary offering. The company said its planned divestiture of its Community Living business to Sevita is expected to close by the end of Q1 2026. BrightSpring also initiated FY 2026 guidance, calling for revenue of USD 14.5 billion to USD 15.0 billion (11.9% to 16.2% growth) and Adjusted EBITDA of USD 760 million to USD 790 million (23.1% to 27.9% growth), excluding Community Living and any future closed acquisitions. It expects the Amedisys and LHC acquisition to contribute approximately USD 30 million in Adjusted EBITDA in 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Brightspring Health Services Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602270600PRIMZONEFULLFEED9662544) on February 27, 2026, and is solely responsible for the information contained therein.